Altimmune's Investigational Alcohol Use Disorder Drug Meets Primary Endpoint in Phase 2 Study

MT Newswires Live07-28

Altimmune's (ALT) investigational drug Pemvidutide met its primary and several secondary endpoints in a phase 2 study for treatment of alcohol use disorder, the company said Tuesday.

A 2.4 mg dose yielded a "statistically significant and clinically meaningful" reduction in heavy drinking days versus placebo, the primary endpoint of the approximately 100-patient study, the company said.

The company also met secondary endpoints including a two-level reduction in World Health Organization Risk Drinking Levels and achieving zero heavy-drinking days versus placebo, the company said.

The drug also showed generally favorable tolerability, the company said.

Based on the data, Altimmune plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration to discuss pemvidutide's path forward in alcohol use disorder, the company said.

Shares of the company were up more than 11% in recent premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment